3D-Conformal Radiation vs Helical Tomotherapy in Prostate Cancer

Official Title

Randomized Phase III Trial of 3D Conformal Radiation Therapy Versus Helical Tomotherapy IMRT in High-Risk Prostate Cancer


In this study we are comparing two forms of radiation therapy. This study is being done because it is not clear at present time whether intensity modulated radiation therapy (IMRT) can reduce side effects of radiation therapy compared to standard radiation therapy (called 3D-Conformal Radiation Therapy).

Trial Description

Primary Outcome:

  • Late rectal toxicity from radiation therapy of the prostate
Secondary Outcome:
  • Acute rectal toxicity, Acute and late bladder toxicity, Disease specific survival at 5 years, Biochemical relapse free survival at 5 years, Local control rates at 5 years, Quality of Life
Radical radiation therapy plays an important role in the management of prostate cancer, yielding comparable long-term outcomes to surgery. Unfortunately, long term disease free survival data using PSA criteria have shown that less than 50% of high-risk patients are free of disease at 10 years. To improve on the results of conventional dose radiation therapy dose escalation with three-dimensional conformal radiation has been employed. Due to the irregular shape of the prostate and the variable motion of this organ there is substantial radiation of adjacent normal surrounding tissue during treatment which results in radiation-induced toxicity. Intensity-modulated radiation therapy (IMRT) is a new form of radiation therapy. Preliminary evidence suggests that IMRT improves the dose distribution during radiation therapy of the prostate. The hypothesis of this study is that IMRT delivered using Helical Tomotherapy can reduce late toxicity of radical radiation therapy as compared to three-dimensional conformal radiation (3DCRT) in high-risk prostate cancer patients.

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society